
  
    
      
        Background_NNP
        Squamous_NNP cell_NN carcinoma_NN of_IN the_DT head_NN and_CC neck_NN is_VBZ
        diagnosed_VBN in_IN over_IN 40_CD ,_, 000_CD Americans_NNPS each_DT year_NN ,_, resulting_VBG in_IN
        over_IN 12_CD ,_, 000_CD annual_JJ deaths_NNS [_NN 1_CD ]_NN ._. Carcinomas_NNP of_IN the_DT head_NN
        and_CC neck_NN are_VBP often_RB associated_VBN with_IN multiple_JJ areas_NNS of_IN
        dysplasia_NN or_CC carcinoma_NN 
        in_IN situ_NN (_( CIS_NNP )_) in_IN noncontiguous_JJ
        mucosa_NN ,_, as_RB well_RB as_IN with_IN the_DT development_NN of_IN second_JJ primary_JJ
        cancers_NNS of_IN the_DT aerodigestive_JJ tract_NN ._. The_DT concept_NN of_IN "_'' field_NN
        cancerization_NN "_'' hypothesizes_NNS that_IN regions_NNS of_IN the_DT mucosal_NN
        epithelium_NN ,_, although_IN normal_JJ in_IN appearance_NN ,_, are_VBP
        "_'' preconditioned_JJ "_'' by_IN chronic_JJ exposure_NN to_TO carcinogenic_JJ
        agents_NNS ,_, thus_RB priming_VBG them_PRP for_IN the_DT subsequent_JJ development_NN of_IN
        invasive_JJ lesions_NNS [_NN 2_CD ]_NN ._.
        The_DT use_NN of_IN modern_JJ molecular_JJ biological_JJ techniques_NNS has_VBZ
        supported_VBN and_CC greatly_RB expanded_VBN our_PRP$ understanding_NN of_IN the_DT
        "_'' cancer_NN field_NN effect_NN "_'' ._. Analysis_NNP of_IN X-_NNP chromosome_NN
        inactivation_NN in_IN female_JJ patients_NNS with_IN multiple_JJ head_NN and_CC neck_NN
        cancers_NNS shows_VBZ that_IN distinct_JJ tumors_NNS arise_VBP from_IN regional_JJ
        clonal_NN growths_NNS of_IN phenotypically_RB normal_JJ ,_, mutated_VBN
        preneoplastic_JJ cells_NNS [_NN 3_CD 4_CD 5_CD ]_NN ,_, a_DT phenomenon_NN similar_JJ to_TO
        that_DT also_RB observed_VBD in_IN liver_NN cancer_NN patients_NNS with_IN cirrhosis_NNS
        [_NN 6_CD ]_NN ._. Long-term_JJ smoking_NN and_CC alcohol_NN abuse_NN are_VBP strongly_RB
        associated_VBN with_IN these_DT clonal_NN growths_NNS in_IN the_DT upper_JJ
        aerodigestive_JJ tract_NN (_( reviewed_VBN in_IN [_NN 7_CD ]_NN )_) ._.
        Frequent_JJ allelic_JJ loss_NN at_IN chromosomal_NN locations_NNS 2_CD q_NN ,_, 3_CD p_NN ,_,
        4_CD q_NN ,_, 6_CD p_NN ,_, 6_CD q_NN ,_, 8_CD p_NN ,_, 8_CD q_NN ,_, 9_CD p_NN ,_, 11_CD q_NN ,_, 13_CD q_NN ,_, 14_CD q_NN and_CC 17_CD q_NN is_VBZ observed_VBN
        in_IN head_NN and_CC neck_NN cancer_NN [_NN 4_CD 8_CD 9_CD 10_CD 11_CD ]_NN ._. Molecular_NNP studies_NNS
        of_IN hyperplastic_JJ ,_, dysplastic_JJ ,_, CIS_NNP ,_, and_CC invasive_JJ head_NN and_CC
        neck_NN lesions_NNS indicate_VBP that_DT loss_NN of_IN heterozygosity_NN at_IN
        chromosomal_NN locations_NNS 3_CD p_NN ,_, 9_CD p_NN and_CC 17_CD p_NN are_VBP early_JJ events_NNS in_IN
        head_NN and_CC neck_NN carcinogenesis_NNS [_NN 4_CD 12_CD ]_NN ._. Specific_JJ tumor_NN
        suppressor_NN genes_NNS ,_, such_JJ as_IN 
        FHIT_NNP (_( 3_CD p_NN 14_CD ._. 2_LS )_) 
        p_NN 16_CD (_( 9_CD p_NN 21_CD )_) ,_, 
        p_NN 53_CD (_( 17_CD p_NN 13_CD ._. 1_LS )_) and_CC 
        RB_NNP 1_CD (_( 13_CD q_NN 14_CD ._. 2_LS )_) have_VBP also_RB been_VBN shown_VBN to_TO
        be_VB mutated_VBN in_IN head_NN and_CC neck_NN cancer_NN [_NN 4_CD 13_CD ]_NN ._. Nevertheless_RB ,_,
        the_DT large_JJ number_NN of_IN additional_JJ chromosomal_NN regions_NNS with_IN
        high_JJ frequencies_NNS of_IN allelic_JJ loss_NN in_IN head_NN and_CC neck_NN cancer_NN
        strongly_RB suggests_VBZ that_IN many_JJ suppressor_NN genes_NNS still_RB remain_VBP
        to_TO be_VB identified_VBN ._.
        The_DT 
        mannose_NN 6_CD -_: phosphate_NN /_NN insulin-like_JJ growth_NN
        factor_NN 2_CD receptor_NN (_( M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN )_) maps_NNS to_TO chromosome_NN
        location_NN 6_CD q_NN 25_CD -_: 27_CD [_NN 14_CD ]_NN ;_: a_DT chromosomal_NN region_NN predicted_VBD to_TO
        contain_VB a_DT head_NN and_CC neck_NN tumor_NN suppressor_NN gene_NN [_NN 10_CD 11_CD ]_NN ._.
        It_PRP encodes_NNS for_IN a_DT receptor_NN that_IN functions_NNS in_IN intracellular_NN
        lysosomal_NN enzyme_NN trafficking_NN ,_, transforming_VBG growth_NN factor_NN
        beta_NN activation_NN ,_, and_CC IGF_NNP 2_CD degradation_NN (_( reviewed_VBN in_IN [_NN 15_CD 16_CD
        ]_NN )_) ._. Granzyme_NNP B_NNP internalization_NN by_IN the_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN is_VBZ also_RB
        required_VBN for_IN cytotoxic_JJ T_NN cells_NNS to_TO induce_VB apoptosis_NNS in_IN cells_NNS
        targeted_VBN for_IN death_NN ,_, resulting_VBG in_IN this_DT receptor_NN being_VBG
        referred_VBN to_TO as_RB a_DT "_'' death_NN receptor_NN "_'' [_NN 17_CD ]_NN ._. Elevated_NNP IGF_NNP 2_CD
        levels_NNS during_IN murine_NN development_NN arising_VBG from_IN M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN
        deficiency_NN result_NN in_IN cardiac_JJ abnormalities_NNS ,_, cleft_NN palate_NN ,_,
        fetal_JJ overgrowth_NN and_CC perinatal_NN lethality_NN [_NN 15_CD 18_CD ]_NN ._.
        Furthermore_RB ,_, large_JJ offspring_NN syndrome_NN frequently_RB observed_VBD
        in_IN cloned_VBN animals_NNS is_VBZ associated_VBN with_IN epigenetic_JJ changes_NNS in_IN
        gene_NN regulation_NN and_CC decreased_VBD 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN [_NN 19_CD ]_NN ._. Thus_RB ,_,
        the_DT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN plays_VBZ a_DT crucial_JJ role_NN in_IN
        regulating_VBG mammalian_JJ fetal_JJ growth_NN and_CC development_NN ._.
        The_DT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN is_VBZ also_RB mechanistically_RB
        involved_VBN in_IN the_DT genesis_NN of_IN human_JJ cancer_NN [_NN 6_CD 20_CD 21_CD 22_CD 23_CD 24_CD
        ]_NN ._. 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
        coupled_VBN with_IN intragenic_JJ loss-of-function_JJ mutations_NNS in_IN the_DT
        remaining_VBG allele_NN is_VBZ a_DT common_JJ event_NN in_IN human_JJ cancers_NNS [_NN 6_CD 20_CD
        21_CD 22_CD ]_NN ._. Inheritance_NNP of_IN a_DT tandem_JJ repeat_NN polymorphism_NN in_IN
        the_DT 3_CD '_POS UTR_NNP of_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN furthermore_RB predicts_VBZ for_IN
        enhanced_JJ susceptibility_NN to_TO oral_JJ cancer_NN [_NN 25_CD ]_NN ._. Moreover_RB ,_,
        tumor_NN cell_NN growth_NN is_VBZ inhibited_VBD when_WRB 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN is_VBZ restored_VBN to_TO
        normal_JJ while_IN it_PRP is_VBZ increased_VBN when_WRB gene_NN expression_NN is_VBZ
        reduced_VBN [_NN 26_CD 27_CD 28_CD 29_CD ]_NN ._. The_DT results_NNS of_IN these_DT mutational_NN
        and_CC functional_JJ studies_NNS clearly_RB demonstrate_VBP that_IN the_DT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN possesses_VBZ the_DT
        characteristics_NNS necessary_JJ to_TO be_VB classified_VBN as_IN a_DT tumor_NN
        suppressor_NN gene_NN [_NN 30_CD ]_NN ._.
        We_PRP tested_VBD in_IN this_DT investigation_NN the_DT hypothesis_NNS that_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN in_IN
        locally_RB advanced_VBD ,_, non-metastatic_JJ squamous_JJ cell_NN carcinomas_NNS
        of_IN the_DT head_NN and_CC neck_NN is_VBZ associated_VBN with_IN poorer_JJR patient_NN
        prognosis_NN ._. The_DT patients_NNS used_VBN in_IN this_DT study_NN were_VBD enrolled_VBN in_IN
        a_DT randomized_JJ trial_NN of_IN twice_RB daily_JJ radiotherapy_NN with_IN or_CC
        without_IN concurrent_JJ chemotherapy_NN [_NN 31_CD ]_NN ._. We_PRP report_VBP herein_NN
        that_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
        occurs_VBZ frequently_RB in_IN head_NN and_CC neck_NN cancer_NN ,_, and_CC that_IN it_PRP
        predicts_VBZ for_IN poor_JJ therapeutic_JJ outcome_NN ._.
      
      
        Methods_NNP
        
          Patient_NNP Population_NNP and_CC Treatment_NNP
          Patients_NNS with_IN locally_RB advanced_VBD but_CC non-metastatic_JJ
          squamous_JJ carcinoma_NN of_IN the_DT head_NN and_CC neck_NN who_WP participated_VBD
          in_IN or_CC who_WP met_VBD eligibility_NN criteria_NNS but_CC declined_VBD
          enrollment_NN in_IN a_DT phase_NN 3_CD trial_NN of_IN hyperfractionated_JJ
          irradiation_NN with_IN or_CC without_IN concurrent_JJ chemotherapy_NN
          constituted_VBD the_DT study_NN population_NN ._. Details_NNS of_IN their_PRP$
          treatment_NN and_CC outcome_NN have_VBP been_VBN published_VBN previously_RB [_NN 31_CD
          ]_NN ._. Briefly_NNP ,_, patients_NNS receiving_VBG radiation_NN therapy_NN alone_RB
          were_VBD given_VBN a_DT continuous_JJ course_NN of_IN 125_CD cGy_NN twice_RB daily_JJ to_TO
          a_DT total_JJ dose_NN of_IN 75_CD Gy_NNP ._. Patients_NNS assigned_VBN to_TO combined_VBN
          modality_NN treatment_NN received_VBD 70_CD Gy_NNP via_IN a_DT split-course_JJ of_IN
          125_CD cGy_NN twice_RB daily_RB ._. They_PRP also_RB received_VBD two_CD cycles_NNS of_IN
          cisplatin_NN and_CC 5_CD -_: fluorouracil_NN during_IN the_DT first_JJ and_CC sixth_JJ
          weeks_NNS of_IN irradiation_NN ._. All_DT protocols_NNS were_VBD approved_VBN by_IN the_DT
          Duke_NNP University_NNP Medical_NNP Center_NNP Institutional_NNP Review_NNP
          Board_NNP ._.
        
        
          Tissue_NNP Microdissection_NNP and_CC M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD RLoss_NNP of_IN
          Heterozygosity_NNP Analysis_NNP
          Microdissection_NNP of_IN malignant_JJ and_CC surrounding_VBG normal_JJ
          non-mucosal_JJ tissue_NN was_VBD performed_VBN as_RB previously_RB described_VBD
          [_NN 6_CD 20_CD 21_CD ]_NN ;_: tumor_NN histology_NN was_VBD confirmed_VBN by_IN a_DT
          pathologist_NN (_( R_NN ._. T_NN ._. Volmer_NNP )_) ._. Paraffin-embedded_NNP sections_NNS (_( 10_CD
          μm_NN in_IN thickness_NN )_) were_VBD microdissected_JJ following_NN
          deparaffinization_NN ,_, and_CC the_DT tissue_NN was_VBD then_RB digested_VBN by_IN
          proteinase_NN K_NNP in_IN tris-_NN EDTA_NNP buffer_NN at_IN 55_CD °_NN C_NNP for_IN 4_CD hr_NN ._. Six_CD
          different_JJ gene-specific_JJ polymorphisms_NNS were_VBD used_VBN to_TO assess_VB
          head_NN and_CC neck_NN tumors_NNS for_IN 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN [_NN
          32_CD 33_CD ]_NN ._.
          A_DT tetranucleotide_NN (_( ACAA_NNP )_) insertion_NN /_NN deletion_NN
          polymorphism_NN in_IN the_DT 3_CD '_POS -_: UTR_NNP of_IN the_DT 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN [_NN 34_CD ]_NN was_VBD detected_VBN with_IN
          2_CD rounds_NNS of_IN nested_JJ polymerase_NN chain_NN reaction_NN (_( PCR_NNP )_) ._. The_DT
          forward_RB and_CC reverse_VB first_JJ round_NN PCR_NNP primers_NNS were_VBD
          KK_NNP *_NN ACAA_NNP *_NN F_NN 1_CD :_: 5_CD '_POS -_: GGAGAGTTTGCCTGTTCTATGCC-_NNP 3_CD '_POS and_CC KK_NNP *_NN ACAA_NNP *_NN R_NN :_:
          5_CD '_POS -_: CAAATCAATCTTTGGGC_NNP AGG-_NNP 3_CD '_POS ,_, respectively_RB ._. The_DT forward_RB
          and_CC reverse_VB second_JJ round_NN PCR_NNP primers_NNS were_VBD KK_NNP *_NN ACAA_NNP *_NN F_NN 2_CD :_:
          5_CD '_POS -_: AGTCAGGAATGGCTGCACC-_NNP 3_CD '_POS and_CC KK_NNP *_NN ACAA_NNP *_NN R_NN :_: 5_CD '_POS -_: CAAATCAATC_NNP
          TTTGGGCAGG-_NNP 3_CD '_POS ,_, respectively_RB ;_: the_DT KK_NNP *_NN ACAA_NNP *_NN F_NN 2_CD primer_NN was_VBD
          end-radiolabeled_JJ with_IN 33_CD P-_NNP dATP_NN prior_RB to_TO PCR_NNP ._. Each_DT round_NN
          of_IN PCR_NNP consisted_VBD of_IN 31_CD cycles_NNS at_IN 94_CD °_NN C_NNP for_IN 20_CD seconds_NNS ,_,
          55_CD °_NN C_NNP for_IN 40_CD seconds_NNS ,_, and_CC 72_CD °_NN C_NNP for_IN 45_CD seconds_NNS ;_: Platinum_NN
          ®_NN Taq_NNP DNA_NNP polymerase_NN (_( GibcoBRL_NNP ,_, Baltimore_NNP ,_, MD_NNP )_) was_VBD used_VBN
          for_IN DNA_NNP amplification_NN ._. The_DT PCR_NNP product_NN (_( 5_CD μl_NN )_) containing_VBG
          the_DT 3_CD '_POS -_: UTR_NNP (_( ACAA_NNP )_) insertion_NN /_NN deletion_NN polymorphism_NN was_VBD
          mixed_VBN with_IN 5_CD μl_NN of_IN formamide-based_JJ stop_NN buffer_NN ,_, heated_VBN to_TO
          95_CD °_NN C_NNP for_IN 10_CD min_NN ,_, placed_VBN on_IN ice_NN ,_, electrophoresed_JJ on_IN a_DT 6_CD %_NN
          acrylamide_NN gel_NN ,_, and_CC then_RB exposed_VBN to_TO film_NN ._.
          Five_CD identified_VBN single_JJ nucleotide_NN polymorphisms_NNS ,_, c_SYM ._.
          901_CD C_NNP >_NN G_NNP (_( exon_NN 6_CD )_) ,_, c_SYM ._. 1197_CD A_DT >_NN G_NNP (_( exon_NN 9_CD )_) ,_, c_SYM ._. 1737_CD A_DT >_NN G_NNP
          (_( exon_NN 12_CD )_) ,_, c_SYM ._. 2286_CD A_DT >_NN G_NNP (_( exon_NN 16_CD )_) ,_, and_CC c_SYM ._. 5002_CD A_DT >_NN G_NNP
          (_( exon_NN 34_CD )_) ,_, were_VBD also_RB analyzed_VBN following_VBG 2_CD rounds_NNS of_IN
          nested_JJ PCR_NNP ;_: the_DT exon_NN specific_JJ forward_RB and_CC reverse_VB primers_NNS
          have_VBP been_VBN previously_RB described_VBN [_NN 32_CD 33_CD ]_NN ._. The_DT exons_NNS
          containing_VBG these_DT polymorphisms_NNS were_VBD PCR_NNP amplified_VBN from_IN
          genomic_JJ DNA_NNP using_VBG PCR_NNP conditions_NNS identical_JJ to_TO those_DT
          described_VBD above_IN ._. The_DT single_JJ nucleotide_NN polymorphisms_NNS used_VBN
          to_TO determine_VB 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
          were_VBD assessed_VBN by_IN direct_JJ sequencing_VBG of_IN PCR_NNP products_NNS
          according_VBG to_TO the_DT manufacturer_NN 's_POS protocol_NN (_( Thermo_NNP
          Sequenase_NNP ,_, USB_NNP Corporation_NNP ,_, Cleveland_NNP ,_, OH_NNP )_) (_( Figure_NN 1_LS )_) ._. 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
          frequency_NN is_VBZ independent_JJ of_IN the_DT polymorphism_NN used_VBN for_IN its_PRP$
          estimation_NN (_( p_NN =_SYM 0_CD ._. 3_LS )_) ._.
          
          Taq_NNP DNA_NNP polymerase_NN can_MD introduce_VB
          sequence_NN errors_NNS during_IN PCR_NNP amplification_NN ,_, and_CC unequal_JJ
          amplification_NN of_IN the_DT two_CD alleles_NNS can_MD result_VB in_IN false_JJ
          positive_JJ detection_NN of_IN loss_NN of_IN heterozygosity_NN ._. Thus_RB ,_, both_DT
          the_DT normal_JJ and_CC tumor_NN DNA_NNP templates_NNS were_VBD amplified_VBN in_IN
          three_CD independent_JJ PCR_NNP reactions_NNS ,_, and_CC assessed_VBD for_IN tumor_NN 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN ._.
          Due_JJ to_TO the_DT potential_NN of_IN contaminating_VBG the_DT tumor_NN tissue_NN
          sample_NN with_IN normal_JJ stroma_NN ,_, allele_NN loss_NN in_IN informative_JJ
          patients_NNS was_VBD defined_VBN as_IN a_DT >_NN 50_CD %_NN decrease_NN in_IN the_DT ratio_NN
          of_IN the_DT polymorphic_JJ band_NN intensities_NNS in_IN the_DT tumor_NN tissue_NN
          versus_CC that_IN in_IN the_DT surrounding_VBG normal_JJ stromal_NN tissue_NN ;_:
          this_DT was_VBD quantified_VBN using_VBG a_DT densitometer_NN ._.
        
        
          Statistical_NNP Analysis_NNP
          Relapse-free_NNP survival_NN represented_VBD the_DT primary_JJ clinical_JJ
          endpoint_NN ._. Locoregional_NNP control_NN was_VBD evaluated_VBN as_IN a_DT
          secondary_JJ endpoint_NN since_IN the_DT vast_JJ majority_NN of_IN head_NN and_CC
          neck_NN cancers_NNS recur_NN either_CC locally_RB at_IN the_DT primary_JJ site_NN or_CC
          regionally_RB in_IN the_DT neck_NN ;_: cause_VB specific_JJ survival_NN was_VBD also_RB
          assessed_VBN ._. All_DT curves_NNS were_VBD computed_JJ using_VBG the_DT Kaplan-_NNP Meier_NNP
          method_NN starting_VBG from_IN the_DT time_NN of_IN study_NN entry_NN ._. Curves_NNP for_IN
          different_JJ subgroups_NNS were_VBD compared_VBN by_IN the_DT Cox-_NNP Mantel_NNP test_NN ._.
          A_DT chi-squared_JJ test_NN was_VBD used_VBN to_TO compare_VB the_DT clinical_JJ
          characteristics_NNS between_IN 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN informative_JJ and_CC excluded_VBN
          patients_NNS and_CC informative_JJ patients_NNS with_IN and_CC without_IN 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN ._. A_DT
          p-value_JJ <_NN 0_CD ._. 05_CD was_VBD considered_VBN to_TO be_VB statistically_RB
          significant_JJ ._.
        
      
      
        Results_NNS
        
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD RLoss_NNP of_IN Heterozygosity_NNP Analysis_NNP
          The_DT study_NN population_NN consisted_VBD of_IN 116_CD patients_NNS
          enrolled_VBD in_IN a_DT phase_NN III_NNP randomized_JJ clinical_JJ trial_NN
          comparing_VBG radiation_NN alone_RB versus_CC radiation_NN plus_CC
          concurrent_JJ chemotherapy_NN for_IN advanced_JJ head_NN and_CC neck_NN cancer_NN
          [_NN 31_CD ]_NN plus_CC an_DT additional_JJ 23_CD patients_NNS who_WP met_VBD all_PDT the_DT
          entrance_NN criteria_NNS but_CC declined_VBD enrollment_NN ._. A_DT total_NN of_IN 52_CD
          tumors_NNS could_MD not_RB used_VBN in_IN this_DT investigation_NN because_IN
          either_DT the_DT tissue_NN slides_NNS were_VBD unavailable_JJ or_CC the_DT DNA_NNP
          could_MD not_RB be_VB PCR_NNP amplified_VBN ._. Of_IN the_DT remaining_VBG 87_CD patients_NNS ,_,
          56_CD (_( 64_CD %_NN )_) were_VBD informative_JJ (_( i_NNP ._. e_SYM ._. polymorphic_JJ )_) ,_, and_CC the_DT
          tumors_NNS in_IN 54_CD %_NN (_( 30_CD /_NN 56_CD )_) of_IN these_DT patients_NNS had_VBD 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
          (_( Figure_NN 1_LS )_) ._. The_DT 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN informative_JJ patients_NNS and_CC
          those_DT not_RB used_VBN in_IN this_DT study_NN were_VBD insignificantly_RB
          different_JJ from_IN each_DT other_JJ for_IN the_DT clinical_JJ
          characteristics_NNS of_IN gender_NN ,_, age_NN ,_, race_NN ,_, smoking_NN history_NN ,_,
          baseline_NN hemoglobin_NN ,_, Karnofsky_NNP performance_NN status_NN ,_, tumor_NN
          resectability_NN ,_, treatment_NN ,_, tumor_NN stage_NN ,_, nodal_NN stage_NN ,_,
          overall_JJ staging_NN and_CC site_NN of_IN primary_JJ tumor_NN (_( Table_NNP 1_LS )_) ._.
        
        
          Clinical_NNP Outcome_NNP
          The_DT median_JJ follow-up_JJ for_IN surviving_VBG patients_NNS enrolled_VBD
          on_IN this_DT trial_NN [_NN 31_CD ]_NN is_VBZ now_RB 76_CD months_NNS (_( range_NN :_: 2_CD to_TO 128_CD
          months_NNS )_) ._. 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
          was_VBD associated_VBN with_IN significant_JJ reductions_NNS in_IN 5_CD year_NN
          relapse-free_JJ survival_NN {_( 37_CD %_NN (_( 95_CD %_NN CI_NNP :_: 20_CD %_NN to_TO 54_CD %_NN )_) vs_NNS ._. 65_CD %_NN
          (_( 95_CD %_NN CI_NNP :_: 46_CD %_NN to_TO 84_CD %_NN )_) ;_: p_NN =_SYM 0_CD ._. 05_CD }_) ,_, locoregional_NN control_NN
          {_( 46_CD %_NN (_( 95_CD %_NN CI_NNP :_: 28_CD %_NN to_TO 64_CD %_NN )_) vs_NNS ._. 76_CD %_NN (_( 95_CD %_NN CI_NNP :_: 58_CD %_NN to_TO 94_CD %_NN )_) ;_: p_NN
          =_SYM 0_CD ._. 03_CD }_) and_CC a_DT non-significant_JJ reduction_NN in_IN cause-specific_JJ
          survival_NN {_( 43_CD %_NN (_( 95_CD %_NN CI_NNP :_: 25_CD %_NN to_TO 61_CD %_NN )_) vs_NNS ._. 69_CD %_NN (_( 95_CD %_NN CI_NNP :_: 49_CD %_NN
          to_TO 89_CD %_NN )_) ;_: p_NN =_SYM 0_CD ._. 1_LS }_) ._.
          Since_IN the_DT clinical_JJ trial_NN demonstrated_VBD a_DT significant_JJ
          benefit_NN for_IN patients_NNS receiving_VBG radiotherapy_NN and_CC
          concurrent_JJ chemotherapy_NN [_NN 31_CD ]_NN ,_, outcome_NN was_VBD also_RB
          analyzed_VBN according_VBG to_TO whether_IN or_CC not_RB patients_NNS received_VBD
          chemotherapy_NN (_( Figures_NNS 2_CD ,_, 3_CD ,_, 4_LS )_) ._. Patients_NNS in_IN the_DT
          radiotherapy_NN (_( RT_NNP )_) ,_, loss_NN of_IN heterozygosity_NN (_( LOH_NNP )_) group_NN had_VBD
          significantly_RB lower_JJR 5_CD year_NN relapse-free_JJ survival_NN {_( 23_CD %_NN
          (_( 95_CD %_NN CI_NNP :_: 2_CD %_NN to_TO 44_CD %_NN )_) vs_NNS ._. 69_CD %_NN (_( 95_CD %_NN CI_NNP :_: 46_CD %_NN to_TO 92_CD %_NN )_) ;_: p_NN =_SYM
          0_CD ._. 02_CD }_) (_( Figure_NN 2_LS )_) ,_, locoregional_NN control_NN {_( 34_CD %_NN (_( 95_CD %_NN CI_NNP :_: 11_CD %_NN
          to_TO 57_CD %_NN )_) vs_NNS ._. 75_CD %_NN (_( 95_CD %_NN CI_NNP :_: 54_CD %_NN to_TO 98_CD %_NN )_) ;_: p_NN =_SYM 0_CD ._. 03_CD }_) (_( Figure_NN
          3_LS )_) and_CC cause_VB specific_JJ survival_NN {_( 29_CD %_NN (_( 95_CD %_NN CI_NNP :_: 5_CD %_NN to_TO 53_CD %_NN )_)
          vs_NNS ._. 75_CD %_NN (_( 95_CD %_NN CI_NNP :_: 54_CD %_NN to_TO 96_CD %_NN )_) ;_: p_NN =_SYM 0_CD ._. 02_CD }_) (_( Figure_NN 4_LS )_) than_IN
          those_DT in_IN the_DT RT_NNP ,_, non_NN LOH_NNP group_NN ._. These_DT results_NNS indicate_VBP
          that_IN 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN allelic_JJ loss_NN results_NNS in_IN
          poor_JJ patient_NN outcome_NN when_WRB RT_NNP alone_RB is_VBZ employed_VBN since_IN all_DT
          other_JJ measured_VBN clinical_JJ characteristics_NNS of_IN the_DT head_NN and_CC
          neck_NN cancer_NN patients_NNS were_VBD comparable_JJ to_TO those_DT in_IN patients_NNS
          with_IN a_DT non-mutated_JJ 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN tumor_NN suppressor_NN gene_NN
          (_( Table_NNP 1_LS )_) ._.
          Patients_NNS in_IN the_DT RT_NNP ,_, LOH_NNP group_NN also_RB fared_VBD worse_JJR than_IN
          those_DT in_IN the_DT combined_VBN modality_NN (_( CM_NNP )_) ,_, LOH_NNP group_NN ,_, although_IN
          the_DT differences_NNS were_VBD not_RB statistically_RB significant_JJ in_IN
          these_DT smaller_JJR subgroups_NNS :_: 5_CD year_NN relapse-free_JJ survival_NN
          {_( 23_CD %_NN (_( 95_CD %_NN CI_NNP :_: 2_CD %_NN to_TO 44_CD %_NN )_) vs_NNS ._. 54_CD %_NN (_( 95_CD %_NN CI_NNP :_: 26_CD %_NN to_TO 82_CD %_NN )_) ;_: p_NN
          =_SYM 0_CD ._. 18_CD }_) ,_, locoregional_NN control_NN {_( 34_CD %_NN (_( 95_CD %_NN CI_NNP :_: 11_CD %_NN to_TO 57_CD %_NN )_)
          vs_NNS ._. 61_CD %_NN (_( 95_CD %_NN CI_NNP :_: 34_CD %_NN to_TO 88_CD %_NN )_) ;_: p_NN =_SYM 0_CD ._. 25_CD }_) and_CC cause_VB
          specific_JJ survival_NN {_( 29_CD %_NN (_( 95_CD %_NN CI_NNP :_: 5_CD %_NN to_TO 53_CD %_NN )_) vs_NNS ._. 59_CD %_NN (_( 95_CD %_NN
          CI_NNP :_: 30_CD %_NN to_TO 88_CD %_NN )_) ;_: p_NN =_SYM 0_CD ._. 12_CD }_) ._. Patients_NNS in_IN the_DT CM_NNP ,_, LOH_NNP group_NN
          had_VBD 5_CD year_NN relapse-free_JJ survival_NN ,_, locoregional_NN control_NN
          and_CC cause_VB specific_JJ survival_NN that_WDT were_VBD statistically_RB
          indistinguishable_JJ from_IN those_DT in_IN the_DT CM_NNP ,_, non_NN LOH_NNP group_NN (_( p_NN
          >_NN 0_CD ._. 2_LS )_) ._. Combined_VBN modality_NN therapy_NN also_RB did_VBD not_RB provide_VB
          any_DT significant_JJ benefit_NN over_IN radiation_NN alone_RB for_IN patients_NNS
          with_IN a_DT non-mutated_JJ tumor_NN 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN (_( p_NN >_NN 0_CD ._. 2_LS )_) ._. Thus_RB ,_,
          patients_NNS with_IN a_DT non-mutated_JJ 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN who_WP received_VBD RT_NNP alone_RB had_VBD
          the_DT same_JJ long-term_JJ outcome_NN as_IN the_DT overall_JJ population_NN of_IN
          patients_NNS who_WP received_VBD RT_NNP and_CC concurrent_JJ chemotherapy_NN [_NN 31_CD
          ]_NN ._. This_DT implies_VBZ that_IN 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN allelic_JJ loss_NN may_MD help_VB to_TO
          identify_VB a_DT group_NN of_IN head_NN and_CC neck_NN cancer_NN patients_NNS who_WP can_MD
          be_VB adequately_RB treated_VBN with_IN RT_NNP alone_RB without_IN exposure_NN to_TO
          the_DT added_VBN morbidity_NN of_IN combined_VBN modality_NN therapy_NN ._.
          The_DT development_NN of_IN second_JJ primaries_NNS was_VBD independent_JJ of_IN
          the_DT 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN mutation_NN status_NN in_IN the_DT
          primary_JJ tumor_NN (_( p_NN =_SYM 0_CD ._. 8_CD )_) ._. Three_CD of_IN the_DT 30_CD (_( 10_CD %_NN )_) patients_NNS
          with_IN 
          M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
          and_CC two_CD of_IN the_DT 26_CD (_( 8_CD %_NN )_) patients_NNS without_IN loss_NN of_IN
          heterozygosity_NN at_IN this_DT locus_JJ developed_VBN second_JJ
          primaries_NNS ._.
        
      
      
        Discussion_NNP
        
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
        occurs_VBZ frequently_RB in_IN human_JJ breast_NN ,_, liver_NN and_CC lung_NN cancer_NN [_NN
        6_CD 20_CD 21_CD 22_CD ]_NN ,_, and_CC the_DT remaining_VBG allele_NN of_IN 30_CD to_TO 50_CD %_NN of_IN
        these_DT tumors_NNS contains_VBZ an_DT intragenic_JJ loss-of-function_JJ point_NN
        mutation_NN in_IN the_DT ligand_NN binding_JJ domains_NNS [_NN 35_CD ]_NN ._. The_DT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN is_VBZ also_RB commonly_RB mutated_VBN in_IN
        gastrointestinal_NN and_CC endometrial_NN malignancies_NNS because_IN its_PRP$
        coding_VBG sequence_NN contains_VBZ a_DT poly-_NN G_NNP region_NN that_WDT is_VBZ a_DT
        mutational_NN target_NN in_IN tumors_NNS with_IN mismatch_NN repair_NN
        deficiencies_NNS and_CC microsatellite_NN instability_NN [_NN 23_CD 24_CD ]_NN ._.
        Functional_NNP studies_NNS show_VBP that_IN the_DT introduction_NN of_IN an_DT
        exogenous_JJ wild-type_JJ 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN into_IN human_JJ colorectal_NN
        cancer_NN cells_NNS with_IN a_DT single_JJ inactivated_JJ allele_NN significantly_RB
        decreases_VBZ growth_NN rate_NN and_CC enhances_VBZ apoptosis_NNS [_NN 26_CD ]_NN ._.
        Conversely_RB ,_, loss_NN of_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN promotes_VBZ cancer_NN
        cell_NN growth_NN by_IN increasing_VBG intracellular_NN signaling_VBG from_IN both_DT
        the_DT insulin-like_JJ growth_NN factor_NN I_PRP receptor_NN and_CC the_DT insulin_NN
        receptors_NNS [_NN 36_CD ]_NN ._.
        We_PRP demonstrate_VBP herein_NN that_DT loss_NN of_IN heterozygosity_NN at_IN the_DT
        
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN locus_JJ in_IN head_NN and_CC neck_NN
        cancer_NN is_VBZ also_RB associated_VBN with_IN poor_JJ patient_NN prognosis_NN ._. Loss_NN
        of_IN heterozygosity_NN in_IN cancer_NN can_MD occur_VB either_CC because_IN of_IN
        chromosomal_NN deletion_NN or_CC somatic_JJ recombination_NN resulting_VBG in_IN
        uniparental_NN disomy_NN [_NN 37_CD ]_NN ._. Comparative_NNP genomic_JJ
        hybridization_NN studies_NNS in_IN head_NN and_CC neck_NN cancer_NN [_NN 10_CD 38_CD ]_NN
        demonstrate_VB that_IN 6_CD q_NN deletion_NN frequency_NN (_( >_NN 50_CD %_NN )_) is_VBZ
        similar_JJ to_TO that_DT which_WDT we_PRP observed_VBD at_IN the_DT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN locus_JJ ._. This_DT provides_VBZ
        evidence_NN that_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN in_IN
        head_NN and_CC neck_NN cancer_NN is_VBZ due_JJ primarily_RB to_TO either_CC gene_NN
        deletion_NN or_CC chromosomal_NN loss_NN rather_RB than_IN somatic_JJ
        recombination_NN ._.
        Since_IN chromosomal_NN deletion_NN can_MD affect_VB more_JJR than_IN one_CD
        gene_NN ,_, 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
        alone_RB does_VBZ not_RB rule_VB out_RP the_DT possibility_NN that_IN other_JJ adjacent_JJ
        genes_NNS also_RB have_VBP a_DT tumor_NN suppressor_NN function_NN in_IN head_NN and_CC
        neck_NN cancer_NN ._. However_RB ,_, our_PRP$ previous_JJ finding_NN ,_, that_IN both_DT
        alleles_NNS of_IN the_DT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN are_VBP mutated_VBN in_IN greater_JJR than_IN
        50_CD %_NN of_IN squamous_JJ cell_NN carcinomas_NNS of_IN the_DT lung_NN [_NN 22_CD ]_NN ,_,
        supports_VBZ our_PRP$ postulate_NN that_IN the_DT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN is_VBZ a_DT key_JJ head_NN and_CC neck_NN
        cancer_NN tumor_NN suppressor_NN gene_NN at_IN chromosome_NN location_NN 6_CD q_NN ._.
        The_DT clinical_JJ trial_NN from_IN which_WDT the_DT tumor_NN specimens_NNS used_VBN
        in_IN this_DT study_NN were_VBD derived_VBN showed_VBD improvements_NNS in_IN
        relapse-free_JJ survival_NN ,_, locoregional_NN control_NN ,_, and_CC overall_JJ
        survival_NN for_IN those_DT patients_NNS randomized_JJ to_TO combined_VBN modality_NN
        therapy_NN [_NN 31_CD ]_NN ._. This_DT investigation_NN established_VBN that_IN
        patients_NNS whose_WP$ tumors_NNS had_VBD 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN and_CC
        were_VBD treated_VBN with_IN radiotherapy_NN alone_RB had_VBD a_DT significantly_RB
        worse_JJR prognosis_NN than_IN their_PRP$ counterparts_NNS with_IN a_DT non-mutated_JJ
        allele_NN ._. Conversely_RB ,_, patients_NNS with_IN an_DT intact_JJ 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN had_VBD a_DT similar_JJ prognosis_NN
        whether_IN they_PRP received_VBD radiotherapy_NN alone_RB or_CC combined_VBN
        modality_NN treatment_NN ._. Thus_RB ,_, our_PRP$ findings_NNS suggest_VBP that_DT head_NN
        and_CC neck_NN cancer_NN patients_NNS with_IN tumor_NN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
        would_MD benefit_VB most_JJS from_IN combined_VBN modality_NN treatment_NN ._.
        The_DT mechanism_NN by_IN which_WDT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN allelic_JJ loss_NN in_IN head_NN and_CC
        neck_NN tumors_NNS increases_VBZ the_DT effectiveness_NN of_IN adjuvant_NN
        chemotherapy_NN is_VBZ presently_RB unknown_JJ ,_, but_CC it_PRP is_VBZ clearly_RB of_IN
        clinical_JJ importance_NN ._. A_DT primary_JJ function_NN of_IN this_DT receptor_NN in_IN
        placental_NN mammals_NNS involves_VBZ the_DT degradation_NN of_IN extracellular_NN
        IGF_NNP 2_CD ._. 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN allelic_JJ loss_NN would_MD
        therefore_RB result_VB in_IN enhanced_VBN cellular_JJ bioavailability_NN of_IN
        this_DT potent_JJ growth_NN factor_NN ,_, thereby_RB potentially_RB increasing_VBG
        both_DT cell_NN proliferation_NN and_CC resistance_NN to_TO apoptosis_NNS [_NN 29_CD ]_NN
        ._. The_DT M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN also_RB facilitates_NNS the_DT activation_NN of_IN TGFβ_NNP ,_, a_DT
        potent_JJ cell_NN growth_NN inhibitor_NN that_WDT is_VBZ secreted_JJ in_IN an_DT
        inactive_JJ form_NN (_( reviewed_VBN in_IN [_NN 15_CD 16_CD ]_NN )_) ._. 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN mutation_NN is_VBZ therefore_RB one_CD
        mechanism_NN by_IN which_WDT cancer_NN cells_NNS can_MD become_VB refractory_JJ to_TO
        TGFβ_NNP 's_POS mitoinhibitory_NN effect_NN ._.
        We_PRP have_VBP previously_RB shown_VBN that_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN mutation_NN in_IN squamous_JJ cell_NN
        carcinoma_NN of_IN the_DT lung_NN is_VBZ highly_RB correlated_JJ with_IN increased_VBN
        TGFβ_NNP concentrations_NNS in_IN both_DT the_DT tumor_NN and_CC patient_NN plasma_NN [_NN
        39_CD ]_NN ._. Elevated_NNP TGFβ_NNP in_IN the_DT latter_JJ stages_NNS of_IN tumor_NN
        progression_NN directly_RB contributes_VBZ to_TO enhanced_JJ tumor_NN
        angiogenesis_NNS ,_, metastasis_NNS formation_NN and_CC a_DT decreased_VBN host_NN
        immune_JJ response_NN (_( reviewed_VBN in_IN [_NN 40_CD ]_NN )_) ._. Together_RB these_DT
        findings_NNS predict_VBP that_IN tumors_NNS with_IN a_DT mutated_VBN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN would_MD be_VB more_RBR resistant_JJ to_TO
        therapy_NN than_IN those_DT with_IN an_DT intact_JJ receptor_NN ._. Moreover_RB ,_, if_IN
        some_DT chemotherapeutic_JJ agents_NNS are_VBP not_RB only_RB directly_RB
        cytotoxic_JJ to_TO cancer_NN cells_NNS ,_, but_CC also_RB reduce_VB tumor_NN production_NN
        of_IN growth_NN factors_NNS ,_, such_JJ as_IN IGF_NNP 2_CD and_CC TGFβ_NNP ,_, adjuvant_NN
        chemotherapy_NN would_MD be_VB more_RBR useful_JJ in_IN treating_VBG tumors_NNS with_IN a_DT
        mutated_VBN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ,_, as_IN observed_VBN in_IN this_DT
        study_NN ._.
        
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN is_VBZ normally_RB imprinted_JJ in_IN
        mice_NNS with_IN only_RB the_DT maternal_NN copy_NN of_IN the_DT gene_NN being_VBG
        expressed_VBN [_NN 41_CD ]_NN ._. In_IN contrast_NN ,_, both_DT copies_NNS of_IN the_DT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN are_VBP expressed_VBN in_IN humans_NNS
        because_IN genomic_JJ imprinting_VBG at_IN this_DT locus_JJ was_VBD lost_VBN in_IN the_DT
        primate_NN lineage_NN approximately_RB 75_CD million_CD years_NNS ago_RB [_NN 42_CD ]_NN ._.
        Importantly_NNP ,_, restoration_NN of_IN biallelic_JJ 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN expression_NN in_IN mice_NNS results_NNS
        in_IN a_DT marked_VBN reduction_NN in_IN offspring_NN weight_NN late_RB in_IN embryonic_JJ
        development_NN that_WDT persists_VBZ into_IN adulthood_NN [_NN 43_CD ]_NN ._. This_DT
        demonstrates_VBZ that_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN allelic_JJ loss_NN or_CC haploid_NN
        insufficiency_NN markedly_RB enhances_VBZ cell_NN proliferation_NN and_CC /_NN or_CC
        survival_NN during_IN fetal_JJ development_NN ._. Therefore_RB ,_, mutation_NN of_IN
        even_RB a_DT single_JJ allele_NN of_IN the_DT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN in_IN human_JJ somatic_JJ cells_NNS is_VBZ
        predicted_VBN to_TO also_RB promote_VB cell_NN growth_NN ._.
        Haploid_NNP insufficiency_NN for_IN tumor_NN suppressor_NN genes_NNS ,_, such_JJ
        as_IN 
        Nf_NNP 2_CD ,_, 
        p_NN 27_CD 
        Kip_NNP 1_CD ,_, 
        p_NN 53_CD ,_, 
        Ptch_NNP ,_, 
        Pten_NNP and_CC 
        TGFβ_NNP ,_, is_VBZ known_VBN to_TO promote_VB tumor_NN
        formation_NN (_( reviewed_VBN in_IN [_NN 44_CD 45_CD ]_NN )_) ._. Yamada_NNP 
        et_CC al_NN ._. [_NN 6_CD ]_NN demonstrated_VBN that_IN in_IN
        patients_NNS chronically_RB infected_VBN with_IN hepatitis_NNP B_NNP and_CC /_NN or_CC
        hepatitis_NNP C_NNP viruses_NNS ,_, the_DT 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN is_VBZ mutated_VBN not_RB only_RB in_IN
        hepatocellular_NN carcinomas_NNS (_( HCCs_NNP )_) ,_, but_CC also_RB in_IN the_DT
        phenotypically_RB normal_JJ hepatocytes_NNS adjacent_JJ to_TO these_DT tumors_NNS ._.
        Interestingly_RB ,_, only_RB one_CD 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN allele_NN is_VBZ inactivated_JJ in_IN
        the_DT adjacent_JJ cirrhotic_JJ tissue_NN even_RB when_WRB both_DT alleles_NNS are_VBP
        mutated_VBN in_IN the_DT HCC_NNP ._. These_DT findings_NNS are_VBP consistent_JJ with_IN
        normal_JJ appearing_VBG ,_, preneoplastic_JJ hepatocytes_NNS forming_VBG clonal_NN
        masses_NNS in_IN the_DT liver_NN because_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN haploid_NN insufficiency_NN
        affords_NNS them_PRP with_IN a_DT selective_JJ growth_NN and_CC /_NN or_CC survival_NN
        advantage_NN relative_JJ to_TO normal_JJ hepatocytes_NNS [_NN 46_CD ]_NN ._.
        The_DT liver_NN is_VBZ not_RB the_DT only_JJ organ_NN in_IN which_WDT regions_NNS of_IN
        normal_JJ appearing_VBG tissue_NN have_VBP a_DT clonal_NN origin_NN ._. Entire_NNP
        lobules_NNS and_CC large_JJ ducts_NNS of_IN normal_JJ breast_NN tissue_NN can_MD be_VB
        derived_VBN from_IN a_DT single_JJ progenitor_NN cell_NN [_NN 47_CD ]_NN ,_, and_CC LOH_NNP at_IN
        various_JJ chromosomal_NN locations_NNS is_VBZ frequently_RB detectable_JJ in_IN
        morphologically_RB normal_JJ lobules_NNS adjacent_JJ to_TO breast_NN tumors_NNS [_NN
        48_CD ]_NN ._. Lung_NNP tumors_NNS and_CC head_NN and_CC neck_NN tumors_NNS that_WDT develop_VBP in_IN
        a_DT localized_JJ region_NN also_RB often_RB have_VBP a_DT common_JJ clonal_NN origin_NN [_NN
        3_CD 4_CD 49_CD ]_NN ._. The_DT high_JJ frequency_NN of_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN
        observed_VBD in_IN the_DT head_NN and_CC neck_NN tumors_NNS in_IN this_DT study_NN suggests_VBZ
        that_IN the_DT phenomenon_NN of_IN "_'' field_NN cancerization_NN "_'' ,_, first_RB
        described_VBN by_IN Slaughter_NNP and_CC his_PRP$ colleagues_NNS [_NN 2_CD ]_NN in_IN 1953_CD ,_,
        may_MD in_IN part_VB result_NN from_IN the_DT clonal_NN proliferation_NN of_IN mucosal_NN
        epithelial_NN cells_NNS with_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN allelic_JJ loss_NN ._.
      
      
        Conclusions_NNP
        The_DT observations_NNS in_IN this_DT study_NN raise_VBP the_DT intriguing_JJ
        possibility_NN that_DT selection_NN of_IN head_NN and_CC neck_NN cancer_NN patients_NNS
        for_IN concurrent_JJ chemotherapy_NN can_MD be_VB based_VBN upon_IN the_DT
        intratumoral_NN mutational_NN status_NN of_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ._. Furthermore_RB ,_, since_IN 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN loss_NN of_IN heterozygosity_NN in_IN
        squamous_JJ cell_NN carcinomas_NNS is_VBZ highly_RB correlated_JJ with_IN an_DT
        elevated_VBD plasma_NN TGFβ_NNP level_NN [_NN 39_CD ]_NN ,_, patient_NN prognosis_NN may_MD
        potentially_RB be_VB assessed_VBN by_IN a_DT simple_JJ blood_NN test_NN ._. This_DT would_MD
        be_VB desirable_JJ since_IN the_DT morbidity_NN of_IN combined_VBN modality_NN
        therapy_NN is_VBZ greater_JJR than_IN that_DT of_IN radiotherapy_NN alone_RB [_NN 50_CD 51_CD
        ]_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' Contributions_NNP
        TAJ_NNP conceived_VBD of_IN the_DT study_NN ,_, performed_VBD LOH_NNP determinations_NNS
        and_CC drafted_VBD the_DT manuscript_NN ._. DMB_NNP provided_VBD patient_NN samples_NNS
        and_CC assisted_VBN in_IN editing_NN of_IN manuscript_NN ._. JKK_NNP ,_, YO_NNP ,_, H-SJ_NNP and_CC XF_NNP
        identified_VBD 
        M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NNP SNPs_NNP and_CC performed_VBN LOH_NNP
        determinations_NNS ._. RTV_NNP confirmed_VBD tumor_NN histology_NN while_IN RWC_NNP
        performed_VBD statistical_JJ analysis_NN of_IN the_DT data_NNS ._. MSA_NNP assisted_VBN in_IN
        experimental_JJ design_NN and_CC editing_NN of_IN manuscript_NN ._. RLJ_NNP
        conceived_VBD of_IN the_DT study_NN ,_, participated_VBD in_IN its_PRP$ design_NN and_CC
        coordination_NN ,_, and_CC assisted_VBN in_IN editing_NN of_IN manuscript_NN ._. All_DT
        authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
      
        List_NN of_IN Abbreviations_NNP
        CIS_NNP ,_, carcinoma_NN 
        in_IN situ_NN ;_: HCC_NNP ,_, hepatocellular_NN
        carcinoma_NN ;_: IGF_NNP 2_CD ,_, insulin-like_JJ growth_NN factor_NN 2_CD ;_: LOH_NNP ,_, loss_NN of_IN
        heterozygosity_NN ;_: M_NNP 6_CD P_NN /_NN IGF_NNP 2_CD R_NN ,_, mannose_NN 6_CD -_: phosphate_NN /_NN insulin-like_JJ
        growth_NN factor_NN 2_CD receptor_NN ;_: PCR_NNP ,_, polymerase_NN chain_NN reaction_NN ;_:
        SNP_NNP ,_, single_JJ nucleotide_NN polymorphism_NN ;_: TGFβ_NNP ,_, transforming_VBG
        growth_NN factor_NN beta_NN ;_: UTR_NNP ,_, untranslated_JJ region_NN ._.
      
    
  
